Business Context and Reporting Period
This Form 8-K is filed by TopSpin Medical, Inc. (not My Size, Inc.) on September 25, 2008. The report details the fulfillment of conditions required to finalize a Settlement Agreement regarding the company's Series A Debentures, originally entered into on July 13, 2008.
Key Financial Metrics and Debt Structure
The filing focuses on the restructuring of debt obligations rather than operational financial performance. Key metrics regarding the debt conversion include:
- Debt Instrument: Series A Convertible Debentures.
- Conversion Ratio: Every 1.00 NIS of principal amount converts into 9 shares of Common Stock.
- Cash Component: Every 1.00 NIS of principal amount converts into 0.25 NIS in cash.
- Outcome: Upon conversion, the Convertible Bonds will be cancelled, delisted, and the original Indenture will terminate.
The filing text does not provide specific values for total revenue, net profit, operating cash flow, or total debt principal outstanding.
Material Changes and Events
The primary material change is the approval by the Tel Aviv Stock Exchange on September 25, 2008, to list the additional shares to be issued to bondholders. This approval satisfied the final condition for the Settlement Agreement to become effective. Consequently, the Supplemental Indenture was executed by the Company, Wilmington Trust Company, and the Co-Trustee.
Outlook, Management Commentary, and Risks
Management has established a definitive timeline for the debt-to-equity conversion:
- Effective Date for Conversion: October 6, 2008.
- Conversion to Shares Date: October 12, 2008.
- Date of Cash Payment: October 15, 2008.
The filing does not contain forward-looking guidance on revenue or earnings, nor does it explicitly list new risks beyond the execution of the settlement terms.
Investor Verification Checklist
- Verify the total principal amount of Series A Debentures outstanding to calculate the exact number of new shares and cash payout.
- Confirm the impact of the 9-to-1 share conversion ratio on existing shareholder dilution.
- Review the full text of the Supplemental Indenture (Exhibit 4.1) for any surviving provisions of the original Indenture.
- Monitor the company's cash position to ensure liquidity is sufficient for the 0.25 NIS per bond cash payment due on October 15, 2008.